Amoy Diagnostics

Amoy Diagnostics, established in 2008 by Professor Zheng Limou, is a prominent player in molecular diagnostics, specifically targeting precision oncology. The company is dedicated to advancing patient care through innovative technologies that deliver high-quality diagnostic products and services, thereby enabling precision medicine. Operating within the Medical Devices & Equipment and Manufacturing sectors, Amoy Diagnostics has built a reputation for its commitment to scientific rigor and clinical application. Its strategic focus on oncology diagnostics positions it at the forefront of personalized healthcare solutions.

The company offers a comprehensive suite of diagnostic solutions, including Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), and nucleic acid extraction products, alongside various specialized diagnostic kits. These advanced tools are designed for healthcare providers and pharmaceutical companies seeking sophisticated diagnostic capabilities. With an employee range of 1,000 - 5,000 individuals, Amoy Diagnostics fosters a culture of innovation and expertise. Meet Amoy Diagnostics's team to understand the driving force behind their scientific advancements and operational excellence.

Amoy Diagnostics generates substantial revenue, reported at $148.6M, underscoring its significant market presence. Primarily based in China, with operations extending across the Asia-Pacific region, the company plays a crucial role in the regional and global precision medicine landscape. Its B2B model focuses on delivering critical diagnostic insights that empower clinicians and researchers. The company's founding year of 2008 and its specialized product portfolio highlight a decade-plus dedication to improving cancer diagnosis and treatment strategies through molecular insights.